SEC Form 4 · accession 0001209191-18-039406
Forte Biosciences, Inc. · FBRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas E Darcy
Director
Period of report
Jun 21, 2018
Accepted (ET)
Jun 25, 2018 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419041
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $8.98 | Jun 21, 2018 | A | 20,000 | A | — | Jun 20, 2028 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The stock option vests and becomes exercisable in 12 monthly installments following the date of grant.